The patient with an odontogenic infection

Quintessence International

Volumn 35, Issue 6, 2004, Pages 482-502

  Dirks, Sarah J ^a   Terezhalmy, Geza T ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Dept of Dental Diagnostic Science   (United States)

Author keywords

Antibiotic; Drug resistance; Odontogenic infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BENZATHINE PENICILLIN; CARBENICILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFIXIME; CEFRADINE; CLARITHROMYCIN; CLOXACILLIN; DICLOXACILLIN; MACROLIDE; METICILLIN; METRONIDAZOLE; MEZLOCILLIN; NAFCILLIN; OXACILLIN; PENICILLIN V; PIPERACILLIN; PROCAINE PENICILLIN; QUINOLONE DERIVATIVE; SULFONAMIDE; TICARCILLIN; TIMENTIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS; CLINICAL FEATURE; DENTAL CARE; DRUG CHOICE; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; GINGIVA DISEASE; GRAM STAINING; HUMAN; OSTEITIS; OSTEOMYELITIS; PULPITIS; REVIEW; SIDE EFFECT; STREPTOCOCCUS; TOOTH INFECTION;

ANTI-BACTERIAL AGENTS; ANTIMETABOLITES; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CELL WALL; DEBRIDEMENT; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; FOCAL INFECTION, DENTAL; HUMANS; PROTEIN SYNTHESIS INHIBITORS; SUBGINGIVAL CURETTAGE;

EID: 2442618888     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Kuriyama T, Karasawa T, Nakagawa K, et al. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol 2000;90:600-608.
2. Greenberg RN, James RB, Marier RL, Wood WH, Sanders CV, Kent JN. Microbiologic and antibiotic aspects of infections in the oral and maxillofacial region. J Oral Surg 1979;37:873-884.
3. Kannagara DW, Thadepalli H, McQuirter JL. Bacteriology and treatment of dental infections. Oral Surg Oral Med Oral Pathol 1980;50:103-109.
4. Von Konow L, Nord CE, Nordenram A. Anaerobic bacteria in dentoalveolar infections. Int J Oral Surg 1981;10: 313-322.
5. Gill Y, Scully C. Orofacial odontogenic infections: Review of microbiology and current treatment. Oral Surg Oral Med Oral Pathol 1990;70:155-158.
6. Sandor GKB, Low DE, Judd PL, Davidson RJ. Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc 1998;64:508-514.
7. Baker KA, Fotos PG. The management of odontogenic infections: A rational for appropriate chemotherapy. Dent Clin North Am 1994;38:699-706.
8. Moenning JE, Nelson CL, Koehler RB. The microbiology and chemotherapy of odontogenic infections. J Oral Maxillofac Surg 1989;47:976-985.
9. Newman MG. Anaerobic oral and dental infection. Rev Infect Dis 1984;6 (suppl 1):S107-S114.
10. Heimdahl A, Von Konow L, Satoh T, Nord CE. Clinical appearance of orofacial infections of odontogenic origin in relation to microbiological findings. J Clin Microbiol 1985;22: 299-302.
11. Konomen E, Nyfors S, Matto J, Asikainen S, Jousimies-Somer H. Beta-lactamase production by oral pigmented Prevotella species isolated from young children. Clin Infect Dis 1997;25(suppl 2):S272-S274.
12. van Winkelhoff AJ, Winkel KG, Barendregt D, Dellemijn-Kippuw N, Stijne A, van der Velden U. Beta-lactamase producing bacteria in adult periodontitis. J Clin Periodontol 1997;24:538-543.
13. Sands T, Pynn BR, Katsikeris N. Odontogenic infections: Microbiology, antibiotics, and management. Oral Health 1995;85:11-28.
14. Sands T, Pynn BR. Odontogenic infections and clindamycin. Univ Tor Dent J 1995;32-33.
15. Williams R. Periodontal disease. N Engl J Med 1990;322: 373-382.
16. Barclay JK. Antibiotics revisited. N Z Dent J 1990;86:44-47.
17. Cioffi GA, Terezhalmy GT, Parlette HL. Citaneous draining sinus tract: An odontogenic etiology. J Am Acad Dermatol 1986;14:94-100.
18. Kotecha M, Browne MK. Mandibular sinuses of dental origin. Practitioner 1981;225:910-915.
19. Kaban LB. Draining skin lesions of dental origin: The path of spread of chronic odontogenic infections. Plast Reconstr Surg 1980;66:711-717.
20. Lewin-Epstein J, Taicher S, Azaz B. Cutaneous sinus tracts of dental origin. Arch Dermatol 1978;114:1158-1161.
21. Scott MJ Jr, Scott MJ Sr. Cutaneous odontogenic sinus. J Am Acad Dermatol 1980;2:521-524.
22. Karp MP, Bernat JE, Cooney DR, Jewett TC Jr. Dental disease masquerading as suppurative lesions of the neck. J Pediatr Surg 1982;17:532-536.
23. Spear KL, Sheradin PJ, Perry HO. Sinus tracts to the chin and jaw of dental origin. J Am Acad Dermatol 1983;8: 486-492.
24. Rart RS, Konf AW. Tumor Conference No. 34: A dental sinus appearing as atypical epithelial hyperplasia that suggested a squamous-cell carcinoma. J Dermatol Surg Oncol 1981;7:208-209.
25. Wright AJ. The penicillins. Mayo Clin Proc 1999;73: 290-307.
26. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999;74:187-195.
27. Wilhelm MP, Estes LP. Vancomycin. Mayo Clin Proc 1999; 74:928-935.
28. Walker RC. The fluoroquinolones. Mayo Clin Proc 1999; 74:1030-1037.
29. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999;74:825-833.
30. Alvarez-Elcoro S, Enzler MJ. The macrolids: Erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74:613-634.
31. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999;74:519-528.
32. Smilack JD. The tetracyclines. Mayo Clin Proc 1999;74: 727-729.
33. Estes L. Review of pharmacokinetics and pharmacodynamics of antibacterial agents. Mayo Clin Proc 1998;73: 1114-1122.
34. Heimdahl A, Nord CE. Treatment of orofacial infections of odontogenic origin. Scand J Infect Dis 1985;46(suppl): 101-105.
35. Flynn TR. Odontogenic infections. Oral Maxillofac Surg Clin North Am 1991;3:311-329.
36. American Dental Asociation, Council on Scientific Affairs. Antibiotic use in dentistry. J Am Dent Assoc 1997;128:648.
37. Hass D, Epstein J, Eggert F. Antimicrobial resistance: Dentistry's role. J Can Dent Assoc 1998;64(7):496-501.
38. Akimoto Y, Nishimura H, Komiya M, et al. Ampicillin concentrations in human serum and dental pulp following a single oral administration. J Nihon Univ School Dent 1984;26:148-154.
39. Massler M, Pawlak J. The affected and infected pulp. Oral Surg Oral Med Oral Pathol 1977;43:929-947.
40. Torneck CD. A report of studies into changes in the fine structure of the dental pulp in human caries pulpitis. J Endod 1981;7:8-16.
41. Huang GTJ, Potente AP, Kim JW, Chugal N, Zhang X. Increased interleukin-8 expression in inflamed human dental pulps. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:214-220.
42. Hanh CL, Falkler WA. Antibodies in normal and diseased pulps reactive with microorganisms isolated from deep caries. J Endod 1992;18:28-31.
43. Rauschenberger CR, Bailey JC, Cootauco CJ. Detection of human IL-2 in normal and inflamed dental pulp. J Endod 1997;23:366-370.
44. Matsushima K, Ohbayashi E, Takeuchi H, Hosoya S, Abiko Y, Yamazaki M. Stimulation of interleukin-6 production in human pulp cells by peptidoglycans from Lactobacillus casei. J Endod 1998;24:252-255.
45. Oguntebi BR, DeSchepper EJ, Taylor TS, White CL, Pink FE. Postoperative pain incidence related to the type of emergency treatment of symptomatic pulpitis. Oral Surg Oral Med Oral Pathol 1992;73:479-483.
46. Nagle D, Reader A, Beck M, Weaver J. Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90: 636-640.
47. Ranta H, Haapasalo M, Ranta K, et al. Bacteriology of odontogenic apical periodontitis and effect of penicillin treatment. Scand J Infect Dis 1988;20:187-192.
48. Fouad AF, Rivera EM, Walton RE. Penicillin as a supplement in resolving the localized acute apical abscess. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:590-595.
49. Meurman JH. Dental infections and general health. Quintessence Int 1997;28:807-811.
50. Harrison JW, Svec TA. The beginning of the end of the antibacterial era? Part II. Proposed solutions to antibiotic use. Quintessence Int 1998;29:223-229.
51. Murray PR, Rosenblatt JE. Penicillin resistance and penicillinase production in clinical isolates of Bacteroides malaninogenicus. Antimicrob Agents Chemother 1977;11: 605-608.
52. Edson RS, Rosenblatt JE, Lee DT. Recent experience with antimicrobial susceptibility of anaerobic bacteria: Increasing resistance to penicillin. Mayo Clin Proc 1982;57:737-741.
53. Kinder SA, Holt SC, Korman KS. Penicillin resistance in subgingival microbiota associated with adult periodontitis. J Clin Microbiol 1986;23:1127-1133.
54. Heimdahl A, Von Konow L, Nord CE. Isolation of beta-lactamase producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections. Arch Oral Biol 1980;25:689-692.
55. Walker C, Gorden J. The effect of clindamycin on the microbiota associated with refractory periodontitis. J Periodontal 1990;61:692-698.
56. Witcher BL, Beirne OR, Smith RA. Beta-lactamase producing Bacteroides melaninogenicus and osteomyelitis of the mandible. J Oral Med 1983;38:17-20.
57. Hackman AS, Wilkins TD. Influence of penicillinase production by strains of Bacteroides melaninogenicus and Bacteroides oralis on penicillin therapy of experimental mixed anaerobic infection in mice. Arch Oral Biol 1976; 21:385-389.
58. Nord CE. Mechanisms of beta-lactam resistance in anaerobic bacteria. Rev Infect Dis 1986;8(suppl):S543-S548.
59. Lewis MAO, Parkhurst CL, Douglas CWI, et al. Prevalence of penicillin resistant bacteria in acute suppurative oral infection. J Antimicrob Chemother 1995;35:785-791.
60. Peterson L. Antibiotics for oral and maxillofacial infections. In: Newman M, Winkelhoff A (eds). Antibiotic and Antimicrobial Use in Dental Practice, ed 2. Chicago: Quintessence, 2001:157-173.
61. Moore PA. Dental therapeutic indications for the newer long-acting macrolide antibiotics. J Am Dent Assoc 1999; 130:1341-1343.
62. McCracken GH. Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J 1997;128:1142-1151.
63. Sanford JP, Low DE, Judd PL, Davidson RJ. Antibacterial treatment options in the management of odontogenic infections. J Can Dent Assoc 1998;64:508-514.
64. Gilbert DN, Moellering RC, Sande MA. Selection of initial empirical antimicrobial therapy on clinical grounds. In: Gilbert DS, Moellering RC, Sande MA (eds). The Sanford Guide to Antimicrobial Therapy. Hyde Park, VT: Antimicrobial Therapy, 1998:2-47.
65. Kuriyama T, Nakagawa K, Karasawa T, Saiki Y, Yamamoto E, Nakamura S. Past administration of beta-lactam antibiotics and increase in the emergence of beta-lactamase-producing bacteria in patients with orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol 2000;89:186-192.
66. Gordon J, Walker C, Hovliaras C. Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results. J Periodontol 1990;61:686-691.
67. Gilmore WC, Jacobus NV, Gorbach SL, Doku HC, Tally FP. A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections. J Oral Maxillofac Surg 1988;46:1065-1070.
68. von Konow L, Kondell PA, Nord CE, Heimdahl A. Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections. Eur J Clin Microbiol Infect Dis 1992;11:1129-1135.
69. Mangundjaja S, Hardjewinata K. Clindamycin versus ampicillin in the treatment of odontogenic infections. Clin Ther 1990;12:242-249.
70. Hupp J. Antibacterial, antiviral, and antifungal agents. Oral Maxillofac Surg Clin North Am 1991;3:273-284.
71. Ballow CH. Cost considerations in oral antibiotic therapy. Adv in Ther 1995;12(4):199-206.
72. Berg JS, Dischler J, Wanger DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: A healthcare problem. Ann Pharmacother 1993;27(9 suppl):S1-S24.
73. DiMatteo MR. Patient adherence to pharmacotherapy: The importance of effective communication. Formulary 1995;30: 596-605.
74. Feldman JA, DeTullio PL. Medication noncompliance: An issue to consider in the drug selection process. Hospital Formulary 1994;29:204-211.
75. Fincham JE, Wertheimer AI. Elderly patient initial noncompliance: The drug and the reason. J Geriatr Drug Ther 1988;2(4):53-62.
76. McCaffrey DJ III, Smith MC, Banahan BF III. Why prescriptions go unclaimed. US Pharm 1993;8:58,60,62,64-65.
77. Safavi KT, Hayward RA. Choosing between apples and apples: Physicians' choices of prescription drugs that have similar side effects and efficacies. J Gen Intern Med 1992; 7:32-37.
78. Watt J, Dixon F, Thompson R, Burgess C, Crane J, Beasley R. The effect of the increased prescription charges on the collection of asthma drugs. N Z Med J 1992;105(932): 153-154.
79. Dajani AS, Taubert KA, Wilson W, Bolger AF, et al. Prevention of bacterial endocarditis: Recommendations by the American Heart Association. J Am Dent Assoc 1997;128:1142-1151.
80. The ADA/AAOS Rxpert Panel. Advisory statement. Antibacterial prophylaxis for dental patients with total joint replacement. J Am Dent Assoc 1997;128:1004-1007.
81. Hersch EV. Adverse drug interactions in dental practice: Interactions involving antibiotics. J Am Dent Assoc 1999;130:236-251.
82. Meechem JG. Polypharmacy and dentistry: 2. Interactions with analgesics and antimicrobials. Dent Update 2002;29: 382-388.
83. American Dental Association Health Foundation Research Institute, Department of Toxicology. Antibiotic interference with oral contraceptives. J Am Dent Assoc 1991;122:79.
84. Archer JSM, Archer DF. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 2002;46:917-923.
85. LaCasa C. California court denies wrongful birth claim. J Law Med Ethics 1996;24:273-274.
86. American Medical Association Council on Scientific Affairs. Drug interactions between antibiotics and oral contraceptives. Available at: www.ama-assn.org/amalpub/ article/2036-2927.html. Accessed 15 July 2003.
87. American Dental Association Council on Scientific Affairs. Antibiotic interference with oral contraceptives. J Am Dent Assoc 2002;133:880.
88. Abramowicz M. Safety of antimicrobial drugs in pregnancy. Handbook of Antimicrobial Therapy, ed 6. The Medical Letter On Drugs and Therapeutics. New Rochelle, NY: Medical Letter, 2002:182-188.
89. Harrison JW, Svec TA. The beginning of the end of the antibacterial era? Part I. The problem: Abuse of the "miracle drugs." Quintessence Int 1998;29:151-162.
90. Handal T, Olsen I. Antimicrobial resistance with focus on oral beta-lactamases. Eur J Oral Sci 2000;108:163-174.
91. Walker CB. The acquisition of antibiotic resistance in the periodontal microflora. Periodontol 2000 1996;10:79-88.
92. Thaler DS. The evolution of genetic intelligence. Science 1994;264:224-225.
93. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-382.
94. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1073.
95. Hawkley PM. The origins and molecular basis of antibiotic resistance. BMJ 1998;317:657-660.
96. Koshland DE. The microbial wars. Science 1992;257:1021.
97. Brisson-Noel A, Arthur M, Courvalin P. Evidence for natural gene transfer from Gram-positive cocci to Escherichia coli. J Bacteriol 1998;170:1739-1745.
98. Trieu-Cuot P, Carlier C, Courvalin P. Conjugative plasmid transfer from Enterococcus faecalis to Escherichia coli. J Bacteriol 1988;170:4388-4391.
99. Higgins NP. Death and transfiguration among bacteria. 1992;17:207-211.
100. Travis J. Possible evolutionary role exposed for "jumping genes." Science 1992;257:884-885.
101. Travis J. Reviving the antibacterial miracle. Science 1994;264:360-362.
102. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992;257:1050-1055.
103. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. N Engl J Med 1994;330:1247-1251.
104. Hughes VM, Datta N. Conjugative plasmids in bacteria of the "pre-antibiotic" era. Nature 1983;302:725-726.
105. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284:1318-1322.
106. Darveau RP, Tanner A, Page RC. The microbial challenge in periodontitis. Periodontol 2000 1997;14:12-32.
107. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
108. Socransky SS, Haffaajee AD. Dental biofilm: Difficult therapeutic targets. Periodontol 2000 2002;28:12-55.
109. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001;9:34-39.
110. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial films. J Clin Microbiol 1999;37:1771-1776.
111. Wright TL, Ellen RP, Lacriox JM, Sinnadurai S, Mittelman MW. Effects of metronidazole on Porphyromonas gingivalis biofilms. J Periodontal Res 1997;32:473-477.
112. Coquet L, Junger GA, Jouenne T. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. J Antimicrob Chemother 1998;42:755-760.
113. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniac biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000;44:1818-1824.
114. Stewart PS. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother 1996; 40:2517-2522.
115. Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficient in biofilms. Biotechnol Bioeng 1998;59:261-272.
116. Kumon H, Tomochika K, Matunaga T, Ogawa M, Ohmori H. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 1994;38:615-619.
117. Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginaka H, Usui T. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: A simple method. Chemotherapy 1997;43:340-345.
118. Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother 1988;22:667-674.
119. Nichols WW, Dorrington SM, Slack MPE, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother 1998;32:518-523.
120. de Beer D, Stoodley P, Roe F, Lewandowski Z. Effects of biofilm structure on oxygen distribution and mass transport. Biotechnol Bioeng 1994;43:1131-1138.
121. Zhang TC, Bishop PL. Evaluation of substrate and pH effects in a nitrifying biofilm. Wat Environ Res 1996;68:1107-1115.
122. Tack KJ, Sabath LD. Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin. Chemotherapy 1985;31:204-210.
123. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 1986;132:1297-1304.
124. Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents. Microbiology 2000;146:547-549.
125. Prigent-Combaret C, Vidal O, Dorel C, Lejeune P. Abiotic surface sensing and biofilm-dependent regulation of gene expression in Escherichia coli. J Bacteriol 1999;181: 5993-6002.
126. Cochran WL, McFeters GA, Stewart PS. Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J Appl Microbiol 2000;88:22-30.
127. Das JR, Bhakoo M, Jones MV, Gilbert P. Changes in the biocide susceptibility of Staphylococcus epidermidis and Escherichia coli cells associated with rapid attachment to plastic surfaces. J Appl Microbiol 1998;84:852-858.
128. Goto T, Nakame Y, Nishida M, Ohi Y. In vitro bactericidal activities of beta-lactamases, amikacin, and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology 1999;53:1058-1062.